Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer

K. Kataoka, K. Nakamura, J. Mizusawa, H. Fukuda, H. Igaki, S. Ozawa, K. Hayashi, K. Kato, Yuukou Kitagawa, N. Ando

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0-68·2) per cent), and in 99-PRE (35·2 (22·6-46·6) per cent) but not in 99-POST (27·7 (27·7-27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1-68·9) per cent; 99-PRE: 55·9 (54·0-59·7) per cent; 99-POST: 44·4 (44·4-44·4) per cent). Conclusion Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration. Heterogeneity is still a problem in surgical RCTs

Original languageEnglish
Pages (from-to)1088-1096
Number of pages9
JournalBritish Journal of Surgery
Volume102
Issue number9
DOIs
Publication statusPublished - 2015 Aug 1

Fingerprint

Phase III Clinical Trials
Esophagectomy
Esophageal Neoplasms
Survival
Drug Therapy
Institutional Practice
Medical Oncology
Neoplasms
Japan
Clinical Trials

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. / Kataoka, K.; Nakamura, K.; Mizusawa, J.; Fukuda, H.; Igaki, H.; Ozawa, S.; Hayashi, K.; Kato, K.; Kitagawa, Yuukou; Ando, N.

In: British Journal of Surgery, Vol. 102, No. 9, 01.08.2015, p. 1088-1096.

Research output: Contribution to journalArticle

Kataoka, K. ; Nakamura, K. ; Mizusawa, J. ; Fukuda, H. ; Igaki, H. ; Ozawa, S. ; Hayashi, K. ; Kato, K. ; Kitagawa, Yuukou ; Ando, N. / Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. In: British Journal of Surgery. 2015 ; Vol. 102, No. 9. pp. 1088-1096.
@article{dca5b966fc444a03aea71ac02bf61983,
title = "Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer",
abstract = "Background Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0-68·2) per cent), and in 99-PRE (35·2 (22·6-46·6) per cent) but not in 99-POST (27·7 (27·7-27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1-68·9) per cent; 99-PRE: 55·9 (54·0-59·7) per cent; 99-POST: 44·4 (44·4-44·4) per cent). Conclusion Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration. Heterogeneity is still a problem in surgical RCTs",
author = "K. Kataoka and K. Nakamura and J. Mizusawa and H. Fukuda and H. Igaki and S. Ozawa and K. Hayashi and K. Kato and Yuukou Kitagawa and N. Ando",
year = "2015",
month = "8",
day = "1",
doi = "10.1002/bjs.9839",
language = "English",
volume = "102",
pages = "1088--1096",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer

AU - Kataoka, K.

AU - Nakamura, K.

AU - Mizusawa, J.

AU - Fukuda, H.

AU - Igaki, H.

AU - Ozawa, S.

AU - Hayashi, K.

AU - Kato, K.

AU - Kitagawa, Yuukou

AU - Ando, N.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Background Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0-68·2) per cent), and in 99-PRE (35·2 (22·6-46·6) per cent) but not in 99-POST (27·7 (27·7-27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1-68·9) per cent; 99-PRE: 55·9 (54·0-59·7) per cent; 99-POST: 44·4 (44·4-44·4) per cent). Conclusion Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration. Heterogeneity is still a problem in surgical RCTs

AB - Background Variations in institutional practice may contribute to different outcomes of cancer treatment. The impact of interinstitutional heterogeneity on outcomes between hospitals after oesophagectomy has not been examined previously using data from surgical clinical trials. Methods The data from two phase III trials for oesophageal cancer were used. Japan Clinical Oncology Group (JCOG) 9204 involved oesophagectomy (92-OP) versus oesophagectomy plus postoperative chemotherapy (92-POST), with accrual from 1992 to 1997. JCOG9907 involved postoperative chemotherapy (99-POST) versus preoperative chemotherapy (99-PRE), with accrual from 2000 to 2006. Hospitals contributing fewer than three patients were excluded. The influence of time and preoperative chemotherapy on interinstitutional heterogeneity related to postoperative complications and 5-year overall survival were evaluated by comparisons within and between these trial groups. Heterogeneity was estimated by a mixed-effects model after adjusting for age, sex, performance status, location of the primary tumour and clinical stage. Results Twelve hospitals in 92-OP (114 patients), 13 in 92-POST (114), 19 in 99-POST (158) and 18 in 99-PRE (154) were eligible. There was considerable heterogeneity in predicted postoperative complications in both groups in JCOG9204 (median 31·3 (range 15·0-68·2) per cent), and in 99-PRE (35·2 (22·6-46·6) per cent) but not in 99-POST (27·7 (27·7-27·7) per cent) from JCOG9907. A similar pattern was seen for predicted overall survival (92-POST: 66·4 (range 64·1-68·9) per cent; 99-PRE: 55·9 (54·0-59·7) per cent; 99-POST: 44·4 (44·4-44·4) per cent). Conclusion Interinstitutional heterogeneity regarding complications and survival after oesophagectomy is a problem that merits wider consideration. Heterogeneity is still a problem in surgical RCTs

UR - http://www.scopus.com/inward/record.url?scp=84937023669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937023669&partnerID=8YFLogxK

U2 - 10.1002/bjs.9839

DO - 10.1002/bjs.9839

M3 - Article

C2 - 26095389

AN - SCOPUS:84937023669

VL - 102

SP - 1088

EP - 1096

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 9

ER -